Cell Therapy in Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is the most common cause of hospitalisation for heart failure. However, only limited effective treatments are available. Recent evidence suggests that HFpEF may result from a systemic proinflammatory state, microvascular endothelial inflammation...
Saved in:
| Main Authors: | Sabina Frljak, Gregor Poglajen, Bojan Vrtovec |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2022-03-01
|
| Series: | Cardiac Failure Review |
| Online Access: | https://www.cfrjournal.com/articleindex/cfr.2021.21 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Stem Cell Therapy in Patients with Chronic Nonischemic Heart Failure
by: Gregor Poglajen, et al.
Published: (2018-01-01) -
Medical Therapy for Heart Failure with Preserved Ejection Fraction
by: Sara Varnado, et al.
Published: (2022-12-01) -
Mesenchymal stromal cells to treat patients with non‐ischaemic heart failure: Results from SCIENCE II pilot study
by: Abbas Ali Qayyum, et al.
Published: (2024-12-01) -
Biomarkers in Heart Failure with Preserved Ejection Fraction
by: Antoni Bayes-Genis, et al.
Published: (2022-06-01) -
Heart Failure with Preserved Ejection Fraction in the Indian Context
by: Rajeev Gupta, et al.
Published: (2025-04-01)